TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

YCANTH

CANTHARIDIN
Dermatology Approved 2023-07-21
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Prescription
First Approved
2023-07-21
Routes
TOPICAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: CANTHARIDIN

YCANTH Approval History

Loading approval history...

What YCANTH Treats

1 indications

YCANTH is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Molluscum Contagiosum
Source: FDA Label

Drugs Similar to YCANTH

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

YCANTH FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

YCANTH Patents & Exclusivity

Latest Patent: Feb 2041
Exclusivity: Jul 2028

Patents (6 active)

US12290651 Expires Feb 19, 2041
US12233042 Expires Aug 22, 2038
US11147790 Expires Aug 22, 2038
US11052064 Expires May 28, 2035

Exclusivity

NCE Until Jul 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.